Does OBINUTUZUMAB Cause Malignant neoplasm progression? 81 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 81 reports of Malignant neoplasm progression have been filed in association with OBINUTUZUMAB (Gazyva). This represents 0.6% of all adverse event reports for OBINUTUZUMAB.
81
Reports of Malignant neoplasm progression with OBINUTUZUMAB
0.6%
of all OBINUTUZUMAB reports
18
Deaths
11
Hospitalizations
How Dangerous Is Malignant neoplasm progression From OBINUTUZUMAB?
Of the 81 reports, 18 (22.2%) resulted in death, 11 (13.6%) required hospitalization.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for OBINUTUZUMAB. However, 81 reports have been filed with the FAERS database.
What Other Side Effects Does OBINUTUZUMAB Cause?
Off label use (1,584)
Neutropenia (1,276)
Febrile neutropenia (955)
Covid-19 (942)
Pyrexia (920)
Thrombocytopenia (889)
Disease progression (831)
Infusion related reaction (789)
Pneumonia (662)
Anaemia (640)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which OBINUTUZUMAB Alternatives Have Lower Malignant neoplasm progression Risk?
OBINUTUZUMAB vs OCELLA
OBINUTUZUMAB vs OCRELIZUMAB
OBINUTUZUMAB vs OCRIPLASMIN
OBINUTUZUMAB vs OCTINOXATE\OCTISALATE\ZINC
OBINUTUZUMAB vs OCTINOXATE\OCTOCRYLENE